[{"id":"4a5c5303-d2d6-439b-bd1d-a7d077defa4f","acronym":"CRESTONE","url":"https://clinicaltrials.gov/study/NCT04383210","created_at":"2021-01-17T17:39:01.678Z","updated_at":"2024-07-02T16:35:40.595Z","phase":"Phase 2","brief_title":"Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors","source_id_and_acronym":"NCT04383210 - CRESTONE","lead_sponsor":"Elevation Oncology","biomarkers":" NRG1","pipe":" | ","alterations":" NRG1 fusion","tags":["NRG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRG1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e seribantumab (MM-121)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 09/29/2020","start_date":" 09/29/2020","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-08-08"},{"id":"6f8d44f4-9674-43e8-8558-1e0785beeed1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01209195","created_at":"2021-01-18T04:51:07.539Z","updated_at":"2024-07-02T16:37:29.278Z","phase":"Phase 1","brief_title":"A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers","source_id_and_acronym":"NCT01209195","lead_sponsor":"Merrimack Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • seribantumab (MM-121)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 10/01/2010","start_date":" 10/01/2010","primary_txt":" Primary completion: 05/01/2014","primary_completion_date":" 05/01/2014","study_txt":" Completion: 07/01/2014","study_completion_date":" 07/01/2014","last_update_posted":"2016-09-08"},{"id":"bd6d8b20-32a4-4a68-a55f-408a1d55f108","acronym":"","url":"https://clinicaltrials.gov/study/NCT00734305","created_at":"2021-01-18T02:45:58.246Z","updated_at":"2024-07-02T16:37:29.401Z","phase":"Phase 1","brief_title":"Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment","source_id_and_acronym":"NCT00734305","lead_sponsor":"Merrimack Pharmaceuticals","biomarkers":" HER-2 • PGR","pipe":"","alterations":" ","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e seribantumab (MM-121)"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 07/01/2008","start_date":" 07/01/2008","primary_txt":" Primary completion: 05/01/2010","primary_completion_date":" 05/01/2010","study_txt":" Completion: 09/01/2013","study_completion_date":" 09/01/2013","last_update_posted":"2016-09-01"},{"id":"5aa0d593-f268-480c-9c28-721d1c00cb91","acronym":"","url":"https://clinicaltrials.gov/study/NCT01151046","created_at":"2021-01-18T04:34:56.387Z","updated_at":"2024-07-02T16:37:32.214Z","phase":"Phase 2","brief_title":"Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer","source_id_and_acronym":"NCT01151046","lead_sponsor":"Merrimack Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exemestane • seribantumab (MM-121)"],"overall_status":"Completed","enrollment":" Enrollment 118","initiation":"Initiation: 06/01/2010","start_date":" 06/01/2010","primary_txt":" Primary completion: 06/01/2014","primary_completion_date":" 06/01/2014","study_txt":" Completion: 09/01/2014","study_completion_date":" 09/01/2014","last_update_posted":"2016-05-12"},{"id":"1c41f74c-6442-43c4-aa52-0726c588a548","acronym":"","url":"https://clinicaltrials.gov/study/NCT01421472","created_at":"2021-01-18T05:51:48.410Z","updated_at":"2024-07-02T16:37:32.428Z","phase":"Phase 2","brief_title":"A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer","source_id_and_acronym":"NCT01421472","lead_sponsor":"Merrimack Pharmaceuticals","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • doxorubicin hydrochloride • cyclophosphamide • seribantumab (MM-121)"],"overall_status":"Completed","enrollment":" Enrollment 196","initiation":"Initiation: 08/01/2011","start_date":" 08/01/2011","primary_txt":" Primary completion: 12/01/2013","primary_completion_date":" 12/01/2013","study_txt":" Completion: 06/01/2014","study_completion_date":" 06/01/2014","last_update_posted":"2016-05-03"}]